Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Genmab A/S Dkk (GNMSF)

Genmab A/S Dkk (GNMSF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 16,451,501
  • Shares Outstanding, K 61,570
  • Annual Sales, $ 3,720 M
  • Annual Income, $ 963,000 K
  • EBIT $ 1,250 M
  • EBITDA $ 1,321 M
  • 60-Month Beta 0.92
  • Price/Sales 4.55
  • Price/Cash Flow 17.08
  • Price/Book 3.02
  • Price/Earnings ttm 17.75
  • Earnings Per Share ttm 15.48
  • Most Recent Earnings $0.55 on 02/17/26
  • Next Earnings Date 05/14/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
252.7000 +4.87%
on 03/31/26
275.3000 -3.74%
on 03/11/26
-25.0000 (-8.62%)
since 02/24/26
3-Month
252.7000 +4.87%
on 03/31/26
352.0000 -24.72%
on 01/14/26
-68.2500 (-20.48%)
since 12/24/25
52-Week
170.0000 +55.88%
on 04/09/25
352.0000 -24.72%
on 01/14/26
+67.4250 (+34.13%)
since 03/28/25

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 284.7333
2nd Resistance Point 275.8667
1st Resistance Point 270.4333
Last Price 265.0000
1st Support Level 256.1333
2nd Support Level 247.2667
3rd Support Level 241.8333

See More

52-Week High 352.0000
Fibonacci 61.8% 282.4760
Last Price 265.0000
Fibonacci 50% 261.0000
Fibonacci 38.2% 239.5240
52-Week Low 170.0000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.